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Abstract
Objectives—To estimate prevalence and determinants of potentially inappropriate prescribing 
(PIP) among US older adults using 2012 Beers criteria.
Design—Retrospective cohort study in a random national sample of Medicare beneficiaries.
Setting—2007–2012 fee-for-service Medicare beneficiaries.
Participants—US population aged >65 years with Part A, B and D enrollment in at least 1 
month during a calendar year (N=38,250 patients; 1,308,116 observations)
Measurement—We used 2012 Beers criteria to estimate the prevalence of ≥1 PIP within each 
calendar month and over a 12-month period using data on diagnoses or conditions present in the 
previous 12 months. To account for the dependence of multiple monthly observations of a single 
person when estimating 95% confidence intervals (CI) we used generalized estimating equations. 
We used logistic regression to identify independent determinants of PIP.
Results—The point-prevalence of PIP decreased from 37.6% (95%CI: 37.0–38.1) in 2007 to 
34.2% (95%CI: 33.6–34.7) in 2012, with a statistically significant 2% (95%CI: 1–3%) decline per 
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year assuming a linear trend. One year period-prevalence declined from 64.9% in 2007 to 56.6% 
in 2012. The strongest predictor of PIP was the number of drugs dispensed. Individuals aged 70 
years or older and those seen by a geriatrician were less likely to receive PIP.
Conclusion—From 2007 to 2012, the prevalence of PIP in US older adults decreased according 
to 2012 Beers criteria but remains high, still affecting a third each month and more than a half over 
12 months. The number of dispensed prescription could be used to target future interventions.
Keywords
potentially inappropriate prescribing; Beers criteria; older adults; database study; 
pharmacoepidemiology; Medicare
INTRODUCTION
Aging is associated with the development of multiple chronic diseases and with increasing 
use of long-term prescription medications to treat these conditions. Potentially Inappropriate 
Prescribing (PIP) is defined as the use of drugs that have a high risk of adverse drug events 
(ADE) relative to their potential benefit, particularly when safer or more effective alternative 
therapies are available for the same condition (1). Studies evaluating the consequences of 
PIP in older adults have demonstrated that PIP leads to an increased risk for adverse clinical 
outcomes, jeopardizing the therapeutic objectives (2–6). PIP is considered a major public 
health problem, given its negative impact on health outcomes, hospitalizations, healthcare 
utilization, cost and mortality (2–6).
Increasing interest in safer and more effective treatment in older adults has led to the 
development of prescribing guidelines that support clinical decisions when choosing 
therapies. Among these, the 2003 Beers criteria are arguably the most widely used in clinical 
practice and research (7–10). Criticism of the 2003 Beers criteria led to a major revision in 
2012 (11,12). The 2012 Beers criteria established an explicit list of unsafe drugs and drug 
combinations that should be avoided, and also includes a list of drug-disease interactions 
(DDI) where the use of some drugs should be avoided in patients with these diseases. 
Additionally, the 2012 revision included a list of drugs that should be used with caution in 
older adults (11).
A recently published study using a subset of 2012 Beers criteria documented an annual PIP 
prevalence of 42.6% in US community-dwelling older adults (13). To our knowledge, there 
are no published studies examining the prevalence of PIP using the complete version of the 
2012 Beers criteria. Therefore, we examined the PIP point-prevalence and 12-month period 
prevalence in older adults using the 2012 Beers criteria, and determined time-trends and 
factors associated with PIP.
METHODS
Using a random sample of Medicare fee-for-service claims and enrollment data, we 
constructed a cohort containing one record per Medicare beneficiary per month between 
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2007 and 2012 in which they utilized their Medicare Part D benefit and were continuously 
enrolled in Medicare Parts A and B for the 12 months prior.
PIP was defined according to 2012 Beers criteria, based on the list of medications and 
medication classes deemed (11) to be inappropriate for use in older patients. The operational 
definition of PIP for this study used all categories of inappropriate prescribing (except for 
insulin dosed on a sliding scale) and the list of drugs to be used with caution included in the 
2012 Beers criteria.
We defined drug classes based on Anatomical Therapeutic Chemical (ATC) codes and a list 
of generic names. We then used an ATC to national drug code (NDC) crosswalk and 
searched generic names to identify all Part D claims for each drug class identified in the 
2012 Beers criteria. Daily dose was estimated based on number of pills dispensed, strength, 
and days supplied and was used when the medication’s inappropriate usage definition was 
defined by excess dosage. Long-term use was defined as more than one month of use based 
on either a dispensing of a refill or prescriptions with >30 days of supply. Potential DDI was 
defined by examining diagnosis codes from Part A & B claims during the 12 months 
preceding the month of the prescription fill.
We defined the point-prevalence of PIP as the total number of older adults who filled 1 or 
more inappropriate prescription divided by the total number of older adults with at least one 
prescription during the calendar month (Figure 1). We defined the 12-month period 
prevalence as the number of older adults with PIP in at least one month during the calendar 
year divided by the total number of adults with at least one prescription during the calendar 
year.
In order to compare the most common PIP according to 2003 Beers criteria and 2012 Beers 
criteria we performed additional analyses using the full list of drugs and conditions 
mentioned for each version.
For each person, we also defined the following potential risk factors for PIP: individual 
characteristics (age, sex, race, region and medical conditions mentioned in Charlson 
Comorbidity Index), and health care utilization (number of distinct generic drugs filled each 
month, and number of emergency department visits, outpatient visits, and hospital 
admissions and physician specialties encountered during the previous 12 months).
We used logistic models and generalized estimating equations (GEE) with an independent 
correlation structure to account for the dependence of multiple monthly observations of a 
single person to estimate 95% confidence intervals (CI). We then fit bivariable and 
multivariable models to examine independent determinants of PIP, as measured using point 
prevalence. All analyses were performed using SAS version 9.3 (SAS Institute, Inc., Cary, 
NC).
The study’s protocol was approved by the Institutional Review Board of the Gillings School 
of Global Public Health, University of North Carolina at Chapel Hill, North Carolina, USA.
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The study sample included 1,308,116 observations from 38,250 patients. The mean ± SD 
age was 77.5±7.8 years (38.2% of them were octogenarians), 65.9% were women, and 
84.9% were white. (Table 1) The most common Charlson diagnoses or conditions during the 
previous 12 months were chronic pulmonary disease (35.5%) and diabetes mellitus without 
complications (35.0%). Polypharmacy defined as use of ≥ 5 drugs was found in 38.6% of the 
patients and 8.6% of the sample was taking 10 or more drugs (mean 4.2 ± 3.6). During the 
previous 12 months, 34.3% and 23.4% of patients had at least one emergency room visit or 
required hospitalization, respectively.
The point-prevalence of PIP decreased from 37.6% (95%CI 37.0–38.1) in 2007 to 34.2% 
(95%CI 33.6–34.7) in 2012, (Figure 2) with a statistically significant 2% (95%CI: 1–3%) 
decline per year from 2007 through 2012 assuming a linear trend. The 12-month period 
prevalence of PIP decreased from 64.9% (95%CI 64.1–65.8) in 2007 to 56.6% (95%CI 
55.9–57.4) in 2012. In 2012, DDI accounted for 16.4% of the point prevalence of PIP and 
30.9% of the 12-month prevalence.
The most frequent PIP according to 2012 Beers criteria based on drug choice or dosing were 
digoxin in doses >0.125 mg/day (5.0%), glyburide (2.8%) and estrogen (2.6%). (Table 2) 
The most frequent PIP among DDI criteria were medications inducing or worsening 
delirium (5.4%), followed by drugs inducing fall and fractures (4.9%) such as 
anticholinergics and sedatives. In contrast, using the 2003 Beers criteria, the most common 
PIP based on drug choice or dosing criteria were propoxyphene (2.4%), oral estrogen (2.1%) 
and clonidine (2.1%); similar to 2012 Beers criteria, anticholinergics and psychotropic drugs 
use among patients with cognitive impairment were the most frequent DDI criteria detected.
Several factors were associated with PIP in multivariable analyses. (Table 3) We report 
patient characteristics and health care utilization factors associated with PIP. The factor most 
strongly associated with PIP was the number of drugs (OR 7.51; 95%CI 7.09–7.94 for 10+ 
drugs vs 1–2). Other independent predictors of PIP included patient characteristics such as 
female sex (OR 1.12; 95%CI 1.07–1.17), residence in the western and southern regions of 
the country, and medical conditions such as congestive heart failure (OR 1.96; 95%CI 1.88–
2.04) and dementia (OR 1.77; 95%CI 1.68–1.87). Having at least one emergency room visit 
during the previous 12 months (OR 1.23; 95%CI 1.19–1.26), and having more than 1 
prescriber in a given month (OR 1.09; 95% CI 1.03–1.16 for 3+ prescribers vs 1) were also 
associated with an increased risk of PIP. An increased risk of PIP was seen among older 
adults with a higher number of emergency room visits and outpatient office visits during 
previous 12 months, and a higher number of prescriptions filled and prescribers in a given 
month.
Older age and Asian or Hispanic race/ethnicity were associated with lower rates of PIP in 
adjusted analyses. People with at least one claim prescribed by a geriatrician were less likely 
to have a PIP (OR 0.89; 95%CI 0.79–0.99).
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This study provides evidence that PIP remains very common for older people in the United 
States. Every month, among older adults who filled at least one prescription in the month, 
one in three received a drug for which the potential harms outweigh the potential benefits. 
Only a small reduction in PIP has occurred since 2007. We also found that more than 50% of 
US older adults being treated with prescription medication received at least one PIP during a 
calendar year. This highlights the importance of a clear PIP prevalence definition for 
interpretation in pharmacoepidemiological studies, and the cumulative nature of this risk to 
older adults.
This study is the first to apply the complete version of 2012 Beers criteria to a nationally 
representative population. A recent systematic review of PIP reported 19 studies produced in 
5 countries, and none used the 2012 Beers criteria (14). Further, most previously published 
studies have modified the 2003 Beers criteria to exclude items that depend on dosage, use 
frequency or diagnoses (15) or have used subsets of the 2012 criteria (13,16,17).
Our estimates of the prevalence of PIP using 2012 Beers criteria are generally higher than 
previously published studies, which have reported inappropriate medication use in 14–
45.5% of community-dwelling older adults in the US (13–15). Additionally, we noted that 
the risk for receiving a PIP decreases with increasing age. Thus, our findings are different 
from previous studies that data on community-dwelling older people suggest that PIP was 
associated with advancing age in most studies (14). This difference may be explained by the 
inclusion of DDI in our definition of PIP, or different Medicare drug coverage and drug 
availability during the study period. Our findings are consistent with previous studies in US 
suggesting that western and southern regions are more likely to receive a PIP (23).
A recent study by Davidoff et al. (13) used the Medical Expenditure Panel Survey (MEPS) 
and estimated an annual prevalence of a subset of the 2012 Beers criteria (i.e., 36 medication 
classes that older adults should avoid) from 2006–2010 ranging from 46% from 2006–2007 
to 41% from 2009–2010; lower than our reported estimates for the same subset of 
medication classes of 56% in 2007 to 48% in 2010. A reason for these discrepant estimates 
may be due to differing methods of prescription medication capture. The MEPS relies upon 
self-report of medication use via interviews using medicine bottles and receipts, while our 
analyses drew upon prescription dispensing records, which are not subject to the same 
potential for underreporting (10). In addition to the subset of 34 medication classes 
evaluated by Davidoff et al., we also examined the prevalence of inappropriate medications 
use among older adults due to DDIs, providing the first complete evaluation of the 2012 
Beers criteria using 52 medication classes.
This study is consistent with other data showing a trend of PIP decreasing over time (18,19). 
However, the relatively high number of drugs taken, and the use of anticholinergic and 
psychotropic drugs remained common among PIP users. Therefore, strategies to improve 
quality of care in older adults should focus strategies to reduce total medications (20) as well 
as anticholinergic burden and psychotropic use specifically (21). A component of successful 
practice change would likely be implementation of pharmacogeriatric training. Geriatricians 
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were less likely to prescribe a PIP, and they are better trained on pharmacogeriatrics and PIP 
consequences. In our study we also found that a previous emergency visit was also a 
predictor of PIP. However, special considerations should be taken into account in the 
emergency setting; in light of the risk of ADEs after the emergency attention, including a 
comprehensive medication reconciliation process and selecting safer alternatives during the 
emergency room visit may enhance the quality and safety of health care and reduce the 
incidence of ADEs.
A lower prevalence of PIP according to 2003 Beers criteria was found; mainly due to the 
older version of the Beers criteria include a shorter list of drugs and drug-disease 
interactions that should be avoided in the older people than 2012 Beers criteria. We also 
found a decrease of prevalence of PIP according to 2003 Beers criteria in 2011 and 2012, 
which can be explained because propoxyphene and their combinations were removed from 
the US market in 2010. (Appendix Table A1 to A4).
It is not surprising that the prevalence of PIP varied between criteria used, clinical setting 
and the operational PIP definition used. For instance, the medical literature rarely 
distinguishes between point-prevalence (e.g., in a given month) and 12-month period 
prevalence (e.g., over a 12 months period). Consistent study methods across 
pharmacoepidemiological prevalence studies have the potential to enhance the value of this 
research by allowing comparison between research findings. However, since overlapping 
lists of the most common PIP still remain frequently prescribed, future interventions to 
improve health of older patients could optimally focus on the list of common PIP, such as 
high dose digoxin, glyburide, anticholinergics, psychotropics, and older medications such as 
propoxyphene, doxazosin and amitriptyline.
Given the consistency of findings across the time and criteria used, the evidence already 
available of the adverse drug effect listed in these criteria are not enough or crystal clear to 
change clinical practice for a more safe and better tolerate pharmacotherapy in older adults. 
Therefore, additional studies evaluating the consequences of adverse effects and benefits of 
specific drugs should provide a concise message to the physicians and health care providers 
about potential risk and alternatives of treatment in case of PIP.
Our study has some limitations. First, if patients have alternative sources of prescription 
coverage or over-the-counter drug utilization (such as some antihistamines or NSAIDs), our 
estimates might underestimate the real burden of PIP. Several categories of medications were 
excluded from the Medicare Part D coverage, such as benzodiazepines and barbiturates, 
some of which are listed in the Beers criteria. Second, while claims data overcome issues of 
recall bias and provide nearly complete information on prescription drug use, medical status 
and healthcare utilization can be underrepresented in a database; therefore, the PIP 
prevalence may be underestimated. Finally, and most importantly, there are no data on the 
reasons why certain prescription choices were made by a specific clinician for a specific 
patient. It should be kept in mind that not all PIPs can be avoided; sometimes the benefits of 
a medication outweigh the risks. Moreover, we cannot be certain that the drugs prescribed 
and dispensed were actually consumed. It should also be noted that the Beers criteria only 
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address potential over prescribing, while not addressing potential under prescribing or use of 
duplicate drug classes (11,12). The last may underestimate the PIP prevalence.
Despite these limitations, our prevalence data improves on prior research. Previous studies 
rarely contained information on drug dosage or patient disease conditions, and thus more 
often underestimate PIP related to underlying disease, and fail to report excessive dosage or 
duration (10,13,14). In contrast, our study included diseases or conditions, doses and 
duration of medication use allowing better estimation of PIP prevalence.
Screening tools such as 2012 Beers criteria may be used to detect potential risks and support 
medical decision-making in clinical practice. This is a tool for continued improvements in 
patient safety, when used in quality improvement interventions for geriatric prescribing. This 
tool also permits a comprehensive understanding of the epidemiology of drug related 
problems for broader public health purposes. Prescribing guidelines are not meant to 
supersede the clinical judgement of the prescriber and are not intended as absolute 
contraindications. The Beers criteria are intended to serve as guidance to reduce risk and 
prevent harm when using medications in older adults. They therefore allow us to assess the 
quality of prescribing in clinical practice at the population level (12).
In conclusion, one in three older adults monthly and one in two older adults yearly are 
exposed to a PIP in the US according to the 2012 Beers criteria, with a slight decrease in the 
PIP prevalence between 2007 and 2012. Factors associated with PIP such as patient 
characteristics (3 or more prescriptions filled in a given month, female sex and western and 
southern regions), and health care utilization (an emergency visit during the previous 12 
months) provide clues on how to improve the quality of drug prescribing among older 
adults. These factors also allow us to identify patients at highest risk for PIP. Further 
research is needed to quantify the effects of PIP on the risk of ADEs such as delirium, falls 
and fractures, health cost and frailty.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Point-Prevalence and 12-Month Prevalence of Potentially Inappropriate Prescribing among 
US Medicare Older Adults between 2007 and 2012 According to 2012 Beers Criteria
PIP: Potentially Inappropriate Prescribing; Point prevalence: defined as PIP prevalence in 
the current month; 12-month prevalence: defined as PIP prevalence in the previous 12 
months. BL: Beers List; defined as potentially inappropriate prescriptions based on drug 
choice, dosage or duration of use. DDI: Drug-Disease Interaction; defined as potentially 
inappropriate prescriptions based on drug-disease interactions. Precision (95%CI) of all 
estimates within +/− 1 percentage point.
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Table 2
The 10 Most Common Potentially Inappropriate Prescribing Based on Drug Choice or Dosing and Drug-
Disease Interaction, Detected Between 2007–2012 According to Beers Criteria 2003 and 2012





PIP (%) PIP (%)
First Digoxin doses >0.125 mg/d (5.0%) Propoxyphene (2.4%)
Second Glyburide (2.8%) Estrogen oral (2.1%)
Third Estrogen with or without progestins (2.6%) Clonidine (2.1%)
Fourth Spironolactone >25 mg/d (2.4%) Amitriptyline (1.7%)
Fifth Amitriptyline (1.8%) Doxazosin (1.6%)
Drug-Disease Interaction
First Delirium - All TCAs, Acths, BZD, chlorpromazine, 
corticosteroids, H2-receptors antagonists, meperidine, sedative 
hypnotics, thioridazine (5.4%)
Cognitive Impairment- Barbiturates, Acths, 
Antispasmodics and muscle relaxants, CNS 
stimulants (2.0%)
Second History of falls or fractures - Anticonvulsants, antipsychotics, 
BZD, non-BZD hypnotics, TCA, SSRIs (4.9%)
Chronic Constipation- CCBs, Acths, and 
TCAs (1.1%)
Third Dementia and cognitive impairment – Acth, BZD, H2-receptors 
antagonists, zolpidem, antipsychotics, chronic and as-needed use 
(4.2%)
Blood clotting disorders or receiving 
anticoagulant therapy – NSAIDs, aspirin, 
dipyridamole, ticlopidine, clopidogrel (1.0%)
Fourth Heart Failure – NSAIDs and COX-2 inhibitors, 
nondihydropyridine CCBs (diltiazem, verapamil), pioglitazone, 
rosiglitazone, cilostazol, dronedarone (3.3%)
Stress Urinary Incontinence – Alpha blockers, 
Acths, TCAs, long acting BZD (0.6%)
Fifth Syncope – AChEIs, Peripheral alpha blockers (doxazosin, 
Prazosin, Terazosin), Tertiary TCAs, Chlorpromazine, 
thioridazine, and olanzapine (2.1%)
Arrhythmias - TCAs (0.4%)
Acths: Anticholinergics; CNS: Central Nervous System; TCA: tricyclic antidepressant; CCB: calcium channel blocker; BZD: Benzodiazepines; 
SSRI: Selective Serotonin Reuptake Inhibitor; NSAIDs: non-steroidal anti-inflammatory drugs; COX: cyclooxygenase; AChEI: 
acetylcholinesterase inhibitor.
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